• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

tetano

Editor, Senior Moderator
Cell Rep


. 2021 Oct 6;109869.
doi: 10.1016/j.celrep.2021.109869. Online ahead of print.
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration


Xilin Wu[SUP] 1 [/SUP], Lin Cheng[SUP] 2 [/SUP], Ming Fu[SUP] 3 [/SUP], Bilian Huang[SUP] 4 [/SUP], Linjing Zhu[SUP] 5 [/SUP], Shijie Xu[SUP] 1 [/SUP], Haixia Shi[SUP] 6 [/SUP], Doudou Zhang[SUP] 5 [/SUP], Huanyun Yuan[SUP] 5 [/SUP], Waqas Nawaz[SUP] 4 [/SUP], Ping Yang[SUP] 7 [/SUP], Qinxue Hu[SUP] 8 [/SUP], Yalan Liu[SUP] 9 [/SUP], Zhiwei Wu[SUP] 10 [/SUP]



Affiliations

Abstract

The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19. Here, we characterize several receptor binding domain (RBD)-specific Nbs isolated from an Nb library derived from an alpaca immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S); among them, three Nbs exhibit picomolar potency against SARS-CoV-2 live virus, pseudotyped viruses, and circulating SARS-CoV-2 variants. To improve their efficacy, various configurations of Nbs are engineered. Nb[SUB]15[/SUB]-Nb[SUB]H[/SUB]-Nb[SUB]15[/SUB], a trimer constituted of three Nbs, is constructed to be bispecific for human serum albumin (HSA) and RBD of SARS-CoV-2. Nb[SUB]15[/SUB]-Nb[SUB]H[/SUB]-Nb[SUB]15[/SUB] exhibits single-digit ng/ml neutralization potency against the wild-type and Delta variants of SARS-CoV-2 with a long half-life in vivo. In addition, we show that intranasal administration of Nb[SUB]15[/SUB]-Nb[SUB]H[/SUB]-Nb[SUB]15[/SUB] provides effective protection for both prophylactic and therapeutic purposes against SARS-CoV-2 infection in transgenic hACE2 mice. Nb[SUB]15[/SUB]-Nb[SUB]H[/SUB]-Nb[SUB]15[/SUB] is a potential candidate for both the prevention and treatment of SARS-CoV-2 through respiratory administration.

Keywords: Delta; Nb15; Nb15-NbH-Nb15; SARS-CoV-2; VHH; bispecific; hACE2 mice; intranasal; nanobody; potent neutralizing.
 
Back
Top Bottom